MAZE Maze Therapeutics, Inc.

Nasdaq mazetx.com


$ 33.30 $ 1.96 (6.27 %)    

Thursday, 30-Oct-2025 15:59:54 EDT
QQQ $ 633.20 nm (nm)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 nm (nm)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 33.22
$ 31.17
$ 26.00 x 300
$ 36.99 x 1
$ 31.17 - $ 34.29
$ 6.71 - $ 34.29
315,584
na
1.45B
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

JP Morgan analyst Anupam Rama maintains Maze Therapeutics (NASDAQ: MAZE) with a Overweight and raises the price target from ...

Core News & Articles

HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $50 price t...

Core News & Articles

Guggenheim analyst Debjit Chattopadhyay maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target fro...

Core News & Articles

HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price targe...

Core News & Articles

BTIG analyst Julian Harrison maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $30 to $37.

 maze-shares-jump-as-investors-bet-big-on-experimental-treatments-potential

Maze's MZE782 showed strong Phase 1 results, supporting once- or twice-daily dosing with increased amino acid excretion and...

Core News & Articles

Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines...

Core News & Articles

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for bo...

Core News & Articles

BTIG analyst Julian Harrison initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Tar...

Core News & Articles

HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and ann...

Core News & Articles

Wedbush analyst Laura Chico initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Outperform rating and announces Pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION